2247 GMT - Monash IVF's share-price fall following this week's profit warning leaves the company more vulnerable to a bid. Jefferies says reasons for Monash IVF lowering FY 2025 profit guidance to some A$27.5 million likely include the discretionary nature of IVF treatment as well as Monash IVF's exposure to Victoria, a state that is facing economic challenges. "We do not expect a sudden turnaround in IVF volumes but highlight there may be corporate interest in IVF if an acquirer is willing to take a longer-term view given favorable industry dynamics," analyst David Stanton says. Monash IVF's shares are down around 47% over the past 12 months. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
May 21, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。